|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
CA2441228A1
(en)
*
|
2001-03-23 |
2002-10-03 |
Aphton Corporation |
Combination treatment of pancreatic cancer
|
|
US20090191232A1
(en)
*
|
2001-05-04 |
2009-07-30 |
Gevas Philip C |
Combination therapy for the treatment of tumors
|
|
US20030021786A1
(en)
*
|
2001-07-09 |
2003-01-30 |
Gevas Philip C. |
Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
|
|
US20060165675A1
(en)
*
|
2002-08-02 |
2006-07-27 |
Richman-Eisenstat Janice Beth |
Modulation of mesenchymal cells via iga-receptors
|
|
US20060020119A1
(en)
*
|
2004-03-29 |
2006-01-26 |
Stephen Grimes |
Monoclonal antibodies to gastrin hormone
|
|
WO2004088326A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Aphton Corporation |
Gastrin hormone immunoassays
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP1570858A1
(en)
|
2004-03-05 |
2005-09-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent
|
|
DK1794586T3
(da)
*
|
2004-09-22 |
2013-05-13 |
Cancer Advances Inc |
Monoklonale antistoffer til progastrin
|
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
RU2423381C2
(ru)
|
2005-07-25 |
2011-07-10 |
Трабьон Фармасьютикалз, Инк. |
Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
|
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
EP2184608B1
(en)
*
|
2007-08-23 |
2016-10-05 |
LSI Medience Corporation |
Non-specific reaction inhibitor
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
EP2127666A1
(en)
*
|
2008-05-28 |
2009-12-02 |
Drug Discovery Factory B.V. |
Method for the treatment or prophylaxis of chronic inflammatory diseases
|
|
US20130195840A1
(en)
*
|
2010-01-13 |
2013-08-01 |
Robert P. Kimberly |
Therapeutics and processes for treatment of immune disorders
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
EP2603520A4
(en)
|
2010-08-10 |
2014-02-19 |
Ecole Polytech |
ERYTHROCYTE BINDING THERAPEUTICS
|
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
EP2465536A1
(en)
*
|
2010-12-14 |
2012-06-20 |
CSL Behring AG |
CD89 activation in therapy
|
|
EP3575794A1
(en)
*
|
2012-02-10 |
2019-12-04 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
|
EP2636684A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Prevention of infection
|
|
BR112014022240A2
(pt)
|
2012-03-09 |
2017-08-01 |
Csl Behring Ag |
composições compreendendo imunoglobulinas semelhantes à secretoras
|
|
EP2636681A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Process for enriching IgA
|
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
SG11201606761RA
(en)
|
2014-02-21 |
2016-09-29 |
Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto |
Glycotargeting therapeutics
|
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
CN107428840A
(zh)
*
|
2015-03-25 |
2017-12-01 |
弗劳恩霍夫应用研究促进协会 |
抗cd89细胞毒素的复合物
|
|
UY36751A
(es)
|
2015-06-26 |
2017-01-31 |
Novartis Ag |
Anticuerpos de factor xi y métodos de uso
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
EP3904880A1
(fr)
*
|
2016-09-30 |
2021-11-03 |
Centre national de la recherche scientifique |
Marqueurs membranaires
|
|
US12188935B2
(en)
|
2016-09-30 |
2025-01-07 |
Centre National De La Recherche Scientifique |
Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
|
|
WO2018106945A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
AU2017383232B2
(en)
|
2016-12-23 |
2024-09-12 |
Novartis Ag |
Factor XI antibodies and methods of use
|
|
WO2018183929A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
US12150978B2
(en)
|
2017-06-15 |
2024-11-26 |
Cancer Advances Inc. |
Compositions and methods for preventing tumors and cancer
|
|
EP3624841A4
(en)
|
2017-06-15 |
2021-01-27 |
Cancer Advances, Inc., |
COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
|
|
WO2018232176A1
(en)
|
2017-06-16 |
2018-12-20 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
|
AR112257A1
(es)
|
2017-06-21 |
2019-10-09 |
Gilead Sciences Inc |
Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
|
|
CA3097369A1
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
EP3790577A4
(en)
|
2018-05-09 |
2022-04-27 |
The University of Chicago |
COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
EP3883635A1
(en)
|
2018-11-19 |
2021-09-29 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
|
CN115666704B
(zh)
|
2019-12-13 |
2025-09-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
KR20230004739A
(ko)
*
|
2020-04-21 |
2023-01-06 |
제이제이피 바이오로직스 에스피. 제트 오.오. |
인간화 항-인간 cd89 항체 및 이의 용도
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
WO2022098084A1
(ko)
*
|
2020-11-06 |
2022-05-12 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
KR102766045B1
(ko)
*
|
2020-11-06 |
2025-02-10 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 향상된 항체
|
|
KR102855679B1
(ko)
*
|
2020-11-06 |
2025-09-04 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
KR102853685B1
(ko)
*
|
2020-11-06 |
2025-09-01 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 증진된 항체
|
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
WO2024218512A1
(en)
|
2023-04-19 |
2024-10-24 |
Centessa Pharmaceuticals (Uk) Limited |
Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
|
|
CN117890576A
(zh)
*
|
2023-12-12 |
2024-04-16 |
深圳市陆为生物技术有限公司 |
一种检测CD89-IgA免疫复合物的试剂、方法及其应用
|
|
WO2025218725A1
(zh)
*
|
2024-04-18 |
2025-10-23 |
徕特康(苏州)生物制药有限公司 |
靶向cd20和cd89的髓细胞衔接子抗体及其用途
|
|
WO2026002175A1
(zh)
*
|
2024-06-27 |
2026-01-02 |
无锡徕特康生物科技有限公司 |
靶向ilt7和cd89的髓细胞衔接子抗体及其用途
|